FY2026 EPS Estimates for Roche Boosted by Erste Group Bank

Key Points

• Erste Group Bank raised Roche’s FY2026 EPS forecast to $3.16 from $3.15, above the $3.06 consensus estimate, and projected FY2027 EPS of $3.42.
• Analyst views remain mixed: Morgan Stanley upgraded Roche to “overweight,” Zacks Research moved it to “hold,” and HSBC downgraded it to “hold.” The stock has a consensus “Hold” rating and a $60 target price.
• Roche shares opened at $55.19, above their 50-day and 200-day moving averages, with a 52-week trading range of $39.50 to $60.85.

Roche Holding AG (OTCMKTS:RHHBY - Free Report) - Stock analysts at Erste Group Bank upped their FY2026 earnings estimates for shares of Roche in a research report issued on Thursday, August 27th. Erste Group Bank analyst H. Engel now anticipates that the company will earn $3.16 per share for the year, up from their previous forecast of $3.15. The consensus estimate for Roche's current full-year earnings is $3.06 per share. Erste Group Bank also issued estimates for Roche's FY2027 earnings at $3.42 EPS.

A number of other analysts also recently issued reports on RHHBY. Zacks Research upgraded shares of Roche from a "strong sell" rating to a "hold" rating in a report on Monday, August 24th. Morgan Stanley raised shares of Roche from an "equal weight" rating to an "overweight" rating and set a $63.00 price objective for the company in a research note on Friday, August 7th. Finally, HSBC lowered shares of Roche from a "buy" rating to a "hold" rating in a research note on Monday, July 6th. Five investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $60.00.

Roche Stock Performance

OTCMKTS:RHHBY opened at $55.19 on Monday. The stock has a 50-day simple moving average of $53.94 and a two-hundred day simple moving average of $52.92. Roche has a 52-week low of $39.50 and a 52-week high of $60.85. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.38 and a quick ratio of 1.12.

Institutional Trading of Roche

Several large investors have recently bought and sold shares of RHHBY. McIlrath & Eck LLC acquired a new position in Roche during the 1st quarter valued at approximately $39,000. Atlas Capital Advisors Inc. acquired a new stake in shares of Roche during the fourth quarter worth $192,000. Pinnacle Wealth Management Advisory Group LLC purchased a new stake in shares of Roche during the first quarter valued at $208,000. Renasant Bank purchased a new stake in shares of Roche during the second quarter valued at $210,000. Finally, Enterprise Financial Services Corp increased its position in shares of Roche by 6.6% in the 1st quarter. Enterprise Financial Services Corp now owns 5,576 shares of the company's stock valued at $277,000 after acquiring an additional 345 shares during the period.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY OTCMKTS: RHHBY.

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source